Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Harry G.M. Heijerman"'
Autor:
Danya Muilwijk, Tessa J. van Paridon, Doris C. van der Heijden, Brenda M. Faber-Bisschop, Domenique D. Zomer-van Ommen, Harry G.M. Heijerman, Cornelis K. van der Ent
Publikováno v:
EClinicalMedicine, Vol 62, Iss , Pp 102116- (2023)
Summary: Background: Generic and disease-specific patient-reported outcome measures (PROMs) may lack relevance and sensitivity on a patient-level in chronic diseases with differential disease expression and high individual variability, such as Cystic
Externí odkaz:
https://doaj.org/article/9952d59b56a44c3cbf2b7666535be796
Autor:
Marcella Burghard, Tim Takken, Merel M. Nap-van der Vlist, Sanne L. Nijhof, C. Kors van der Ent, Harry G.M. Heijerman, H.J. Erik Hulzebos
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 16 (2022)
Objectives: [1] To investigate the cardiorespiratory fitness (CRF) levels in children and adolescents with cystic fibrosis (CF) with no ventilatory limitation (ventilatory reserve ⩾ 15%) during exercise, and [2] to assess which physiological factor
Externí odkaz:
https://doaj.org/article/3c0e6f4ef1c8407c886d1d8c5b194ab9
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 6, p 458 (2021)
For many people with cystic fibrosis (pwCF), CFTR modulators will be the cornerstone of their treatment. These modulators show robust treatment effects at group level in pwCF with specific mutations. The individual effect however, is variable. In thi
Externí odkaz:
https://doaj.org/article/6cab2329ab064faf9aab5d8478ce5844
Autor:
Gitte Berkers, Peter van Mourik, Annelotte M. Vonk, Evelien Kruisselbrink, Johanna F. Dekkers, Karin M. de Winter-de Groot, Hubertus G.M. Arets, Rozemarijn E.P. Marck-van der Wilt, Jasper S. Dijkema, Maaike M. Vanderschuren, Roderick H.J. Houwen, Harry G.M. Heijerman, Eduard A. van de Graaf, Sjoerd G. Elias, Christof J. Majoor, Gerard H. Koppelman, Jolt Roukema, Marleen Bakker, Hettie M. Janssens, Renske van der Meer, Robert G.J. Vries, Hans C. Clevers, Hugo R. de Jonge, Jeffrey M. Beekman, Cornelis K. van der Ent
Publikováno v:
Cell Reports, Vol 26, Iss 7, Pp 1701-1708.e3 (2019)
Summary: In vitro drug tests using patient-derived stem cell cultures offer opportunities to individually select efficacious treatments. Here, we provide a study that demonstrates that in vitro drug responses in rectal organoids from individual patie
Externí odkaz:
https://doaj.org/article/dc8d3a11cbb948418c73a2e8f5b11051
Autor:
Jacquelien J. Noordhoek, Joshena Jeyaratnam, Domenique Zomer, Vincent A.M. Gulmans, Cornelis K. van der Ent, Harry G.M. Heijerman
Publikováno v:
Journal of Cystic Fibrosis. 22:172-178
The Dutch CF Foundation (NCFS) developed a quality improvement program, to assess and improve quality of care in all CF centers in The Netherlands. Criteria to assess quality of care from the patient perspective were defined, and quality of care was
Autor:
Harry G.M. Heijerman, Renske van der Meer, Jeffrey M. Beekman, Gitte Berkers, Cornelis K. van der Ent, Joshena Jeyaratnam
Publikováno v:
Journal of Cystic Fibrosis. 20:e63-e66
Substantial progress has been made in the treatment of Cystic fibrosis due to introduction of CFTR modulators. However, little is known about the long term side effects of treatment with these drugs. We here present a 7 year old girl with CF who pres
Autor:
C. Kors van der Ent, Renske van der Meer, Sylvia F. Boj, Robert G.J. Vries, Harry G.M. Heijerman, Peter van Mourik, Paul K. Audhya, Jamie R Doyle, Jeffrey M. Beekman, Zheng Jason Yuan, N. Kinnman, Gitte Berkers
Publikováno v:
Journal of Cystic Fibrosis. 20:761-767
Background Previous in vitro organoid data showed A455E–CFTR, a rare CFTR mutation with 4.1% prevalence in the Netherlands, responds to lumacaftor/ivacaftor (LUM/IVA). We explored LUM/IVA's clinical efficacy in people with CF and ≥1 A455E–CFTR
Autor:
Harry G.M. Heijerman, Joost Raaphorst, Baziel G.M. van Engelen, Peter J. Wijkstra, Charlotte Seijger, Nadine Stigter, Judith M. Vonk
Publikováno v:
Respiration, 100, 154-163
Respiration, 100(2), 154-163. S. Karger AG
Respiration, 1-10. KARGER
STARTPAGE=1;ENDPAGE=10;ISSN=0025-7931;TITLE=Respiration
Respiration
Respiration, 100, 2, pp. 154-163
Respiration, 100(2), 154-163. S. Karger AG
Respiration, 1-10. KARGER
STARTPAGE=1;ENDPAGE=10;ISSN=0025-7931;TITLE=Respiration
Respiration
Respiration, 100, 2, pp. 154-163
Background: Non-invasive home mechanical ventilation (HMV) is a complex treatment in myotonic dystrophy type 1 (DM1) patients, due to a presumed poor adherence, variable symptom improvement, and uncertainty regarding survival benefits. Objectives: We
Autor:
Harry G.M. Heijerman, S. Schotman, M.M.M. van Oirschot-van de Ven, S. Michel, Bente L. Aalbers, K.M. de Winter-de Groot, Regina W. Hofland, C.K. van der Ent, M.A. Kruijswijk, A.C. de Kiviet, H.G.M. Arets
Publikováno v:
Journal of Cystic Fibrosis. 19:654-658
Objective The first available CFTR modulator combination for homozygous F508del patients, lumacaftor/ivacaftor, has not been tested in patients with percentage predicted (pp)FEV1 > 90 in the phase III trials. The objective of this study is to share r
Autor:
Sjoerd G. Elias, Gitte Berkers, Harry G.M. Heijerman, Rozemarijn E.P. Marck – van der Wilt, Renske van der Meer, Margot Geerdink, E. Kruisselbrink, S. Michel, Cornelis K. van der Ent, Jeffrey M. Beekman, Hans Clevers, Karin de Winter-de Groot, Rob Vries, Johanna F. Dekkers, Frank P. Vleggaar, Annelotte M. Vonk
Publikováno v:
Journal of Cystic Fibrosis. Elsevier B.V.
Background CFTR function measurements in intestinal organoids may help to better characterise individual disease expression in F508del homozygous people. Our objective was to study correlations between CFTR function as measured with forskolin-induced